Joint clinical assessments (JCAs) are one of the most important elements of the EU Health Technology Assessment (HTA) Regulation, which will enter into force from January 2025, initially for new cancer medicines and advanced therapy medicinal products that are granted marketing authorizations by the European Commission.
The Member State Coordination Group on HTA (HTA CG), which was established under the new regulation, recently adopted two guidance documents focused on
Key Takeaways
-
The HTA CG, established under the new EU HTA Regulation, has published guidance for member states and assessors around the scoping and reporting of JCAs, a key part of the new regulation.
-
The information is valuable for pharmaceutical companies as it can be used to help them prepare their JCA dossiers
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?